Core Viewpoint - The company, identified as a synthetic biology giant, has shown rapid growth in revenue, increasing from 250 million in 2015 to 2.18 billion in 2024, achieving record scale [4]. Group 1: Revenue and Profit Trends - In Q1 2025, the company continued its revenue growth from 2024, reporting an operating income of 687 million, a year-on-year increase of 37.2%, while net profit was 51 million, a decline of 41% year-on-year [6]. - Net profit has grown from 43 million in 2015 to 449 million in 2023, but the growth halted in 2024, with net profit reported at 190 million, a year-on-year decrease of 57.8% [8]. Group 2: Business Cycle Inquiry - There is a question regarding whether the business exhibits cyclical characteristics, as indicated by the contrasting trends in revenue and profit [7].
业绩八年10倍！合成生物小巨人迎头撞上逆周期，靠技术能否破局？
市值风云·2025-08-05 10:08